Bristol Myers Squibb Slashes Key Drug Prices by Up to 90% Amid Political Pressure

Bristol Myers Squibb (BMS) has implemented significant price reductions ranging from 40% to 90% on three of its major prescription medications. The drugs affected by this move include Sotyktu, Zeposia, and Orencia SC, which have been listed on a government discount platform. This strategic decision follows intensified pressure from the U.S. administration regarding tariffs and the broader push to lower healthcare costs. BMS joins other industry leaders such as Amgen and GSK, who have recently taken similar steps to offer discounted medications. Market analysts suggest that these massive price cuts are likely to compress profit margins and impact the company's overall revenue. The move highlights the growing regulatory challenges facing the pharmaceutical sector as political scrutiny over drug pricing intensifies.